Desktop version

Home arrow Sociology

  • Increase font
  • Decrease font

<<   CONTENTS   >>

Additional NAD Research, Inc., Partnership Studies Underway or Planned

A second study by NAD Research, Inc., led by Susan Broom, examined the response to IV NAD+ treatment in previous patients seeking treatment for alcohol addiction, opiate addiction, and neurodegenerative disease. Armed with baselines from the pharmacokinetic studies, we are examining whether the NAD+ treatment delivered the anticipated increase in plasma NAD+ and its metabolites. Preliminary findings are promising, and final results are expected in 2019.

We are also working to establish collaborative relationships with other researchers. A recent example involves a study by the Center of Magnetic Resonance Research at the University of Minnesota Medical School to measure NAD/NADH ratios in the brain utilizing a powerful MRI technique (In Vivo NAD+ Assay - Minn MRI Study). This study, which involved but a single individual, showed a dramatic increase in ATP production from a single dose of intravenous NAD+. We are currently designing an IRB-approved study to evaluate the cellular energy levels in the brains of additional healthy volunteers following a single dose of IV NAD+.

The implications of this study could be profound. In addition to validating the clinical results we see with intravenous NAD+ in detoxing addiction patients, a dramatic increase in brain cell energy levels could explain why Alzheimer’s patients show' improvement following intravenous NAD+ treatment and why we see such dramatic improvements in Parkinson’s, CTE, and TBI patients following intravenous NAD+.

The next clinical studies in the queue include examining the response of alcohol-addicted patients to IV NAD+ versus standard of care and examining the response of PTSD patients to IV NAD+. These studies are in the design phase and currently seeking funding.

NAD Research, Inc., is guided by a highly qualified Board of Advisors. Led by co-chairs, Dr. Krishna Doniparthi and Dr. Susan Broom, members include Dr. Ross Grant, Dr. Jade Berg, Dr. Jim Watson. Dr. Elizabeth Stuller. Dr. Ken Starr, Dr. Walker Dixon, Dr. Halland Chen, Dr. David Lefer, Dr. Tom Sharp, and Dr. Richard Mestayer.

Many paths for research have developed, and it is our hope that clinical findings regarding the myriad uses and strategies for positively impacting health by way of NAD+ will emerge. We have no doubt that there wall be more than three or four articles over the next 10 years.


  • 1. Bollet Alfred J., Politics and pellagra: the epidemic of pellagra in the US in the early twentieth century. Fate Medical Journal of Biology and Medicine, 65, 1992, pp. 211-221.
  • 2. Harris H.F., A case of ankylostomiasis presenting the symptoms of pellagra. Translational Medicine Association of Georgia, 1902, pp. 220-227.
  • 3. Searcy G.H., An epidemic of acute pellagra. Translator Medicine Association State of Alabama, 1907, pp. 387-392.
  • 4. Searcy G.H.. An epidemic of acute pellagra. JAMA, 37(1). 1907, p. 49.
  • 5. Koehn C.J., Elvehjem C.A., Further studies on the concentration of the anti-pellagra factor. Journal of Biological Chemistry, 118(3), 1937, pp. 693-699.
  • 6. Ottenello P., II Complesso aneurina-vitamina PP nella cura del morfinismo e di altre intossi-cazioni voluttuaire/The use of thiamine and niacin in the detoxification of morphine addiction. Minerva Medico, 1948, pp. 213-215.
  • 7. Hoffer A., Osmond H., Smythies J., Schizophrenia: a new' approach II. Results of a year’s research. Journal of Mental Science, 100(418), 1954. pp. 29-45.
  • 8. Smith R.F., Status report concerning the use of megadose nicotinic acid in alcoholics. Orthomolecular Psychiatry, 3(4), 1974.
  • 9. Harney Malachi L., Current Provisions and Practices in the United States of America Relating to the Commitment of Opiate Addicts. United Nations Office on Drugs and Crime, 1962, pp. 11-23.
  • 10. Verster J.P., Alternative treatment of problem drinkers with DPN™: a brief overview'. The Journal of Modern Pharmacy, 2003, p. 22.
  • 11. Verw'ey T., NAD+ Therapy: Too Good to Be True? Alkogen e-book published on the internet in 2003 and available free from many online sources, or E-Mail This email address is being protected from spam bots, you need Javascript enabled to view it
  • 12. Broom S.I., Carson J., Cook D., Hotard P, Mestayer R., Norris P, Simone K., Stuller E., Intravenous administration of nicotinamide adenine dinucleotide significantly reduces self-reported craving ratings associated with opiate and alcohol withdrawal. Society of Neuroscience Poster Presentation, 2014.
  • 13. Wu L.E., Sinclair D., The elusive NMN transporter is found. Nature Metabolism, 1(1), 2019, pp. 8-9.
  • 14. Giulano V., Watson J.,
  • 15. Zhou M, Ottenberg G., Sferrazza G.F., Hubbs C., Fallahi M., Rumbaugh G., Brantley A.F., Lasmezas C., Neuronal death induced by misfolded prion protein is due to NAD+ depletion and can be relieved in vitro and in vivo by NAD+ replenishment. Brain, 138(4), 2015, pp. 992-1008.
  • 16. Higdon J., Drake V., Delage B., Meyer-Ficca M., Niacin. Linus Pauling Institute Micronutrient Information Center,
  • 17. Massudi H., Grant R., Braidy N., Guest J., Farnsworth B., Guillemin G.J., Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLOS ONE, 2012. urnal.pone.0042357.
  • 18. Grant R., Berg J., Mestayer R.F., Braidy N„ Bennett J., Broom S., Watson J., A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6-hour intravenous infusion of NAD+. Frontiers in Aging Neuroscience, 2019.
<<   CONTENTS   >>

Related topics